NDAORALTABLET
Approved
Jan 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
13
Data completeness
4/8 — Partial
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAVAYSA (edoxaban tosylate) is an oral Factor Xa inhibitor approved in 2015 for the treatment of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. It is a small-molecule anticoagulant that works by selectively inhibiting Factor Xa, thereby reducing thrombin generation and preventing clot formation.
$5MPart D
LOE ApproachingDeclining
1.9 years to LOEWith LOE approaching in 2028, the SAVAYSA brand team is transitioning into a defensive posture focused on patient retention and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Started Jun 2020
666 enrolled
Non-valvular Atrial Fibrillation
Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
Started Jul 2019
1,600 enrolled
Atrial FibrillationRecurrent Venous Thromboembolism
Resolution of Thrombi in Left Atrial Appendage With Edoxaban
Started May 2019
36 enrolled
Atrial FibrillationLeft Atrial Appendage Thrombosis
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
Started Feb 2019
234 enrolled
Atrial Fibrillation
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
Started May 2018
168 enrolled
Cardiac Disease
Worked on SAVAYSA at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.